Physician profile
Da Zhang
NPI 1841547528
$5,071.74
in general payments reported to CMS, 2019-2025
9 companies · $3,899 in 2025
The $3,899 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $94.06 · 2021: $86.77 · 2022: $666 · 2023: $127 · 2024: $86.03 · 2025: $3,899.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,680 · Travel and Lodging: $879 · Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,680.25 |
| Travel and Lodging | $878.76 |
| Food and Beverage | $553.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,680.25 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,819.95 | 2022-2025 | Ofev |
| Novo Nordisk INC | $323.73 | 2019-2022 | |
| Boston Scientific Corporation | $125.39 | 2025 | Emblem Mri S-Icd |
| United Therapeutics Corporation | $86.03 | 2024 | Tyvaso |
| Janssen Pharmaceuticals, INC | $36.39 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Da Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.